The outcomes in the COMPASS trial of rivaroxaban to treat patients with peripheral artery disease have been very positive, and a new analysis has looked at the cost impact of bringing the drug to ...

Dr Andre Lamy (McMaster University, Hamilton, ON) discusses off- or on-pump CABG surgery with Dr Alexandra Lansky (Yale University, New Haven, CT). Filmed at ACC 2012.

The analysis presented at the American Heart Association looks strictly at healthcare costs, but a broader cost-effectiveness study is planned that will consider drug costs as well as effect on ...

CHICAGO -- A large randomized trial comparing bypass surgery done with a heart-lung machine (on pump) and without it (off pump) found no differences in results between techniques overall but some ...

Space to play or pause, M to mute, left and right arrows to seek, up and down arrows for volume. Norman Swan: Let's stay with the heart, but to heart surgery for blocked arteries, known as coronary ...

ANAHEIM, CA—Adding low-dose rivaroxaban (Xarelto; Bayer/Janssen) to low-dose aspirin reduces costs associated with events and procedures in patients with stable atherosclerotic vascular disease, ...

CHICAGO, IL—RBT-1, a novel pharmacologic approach to preconditioning, appeared beneficial in patients undergoing CABG and/or valve surgery in an interim analysis of the phase II START trial. The ...

Administering tranexamic acid (TxA), a drug used to reduce bleeding during heart surgery, topically rather than intravenously did not meet its primary endpoint of reducing seizures and was stopped ...